JP2024540402A - 新規オーリスタチン類似体およびその免疫複合体 - Google Patents

新規オーリスタチン類似体およびその免疫複合体 Download PDF

Info

Publication number
JP2024540402A
JP2024540402A JP2024527084A JP2024527084A JP2024540402A JP 2024540402 A JP2024540402 A JP 2024540402A JP 2024527084 A JP2024527084 A JP 2024527084A JP 2024527084 A JP2024527084 A JP 2024527084A JP 2024540402 A JP2024540402 A JP 2024540402A
Authority
JP
Japan
Prior art keywords
compound
methyl
int
mmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540402A5 (enExample
Inventor
ホイ リィ,リチャード
ジュン リー,ドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adcentrx Therapeutics Inc
Original Assignee
Adcentrx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc filed Critical Adcentrx Therapeutics Inc
Publication of JP2024540402A publication Critical patent/JP2024540402A/ja
Publication of JP2024540402A5 publication Critical patent/JP2024540402A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024527084A 2021-11-03 2022-11-02 新規オーリスタチン類似体およびその免疫複合体 Pending JP2024540402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US63/275,177 2021-11-03
US202163295476P 2021-12-30 2021-12-30
US63/295,476 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (2)

Publication Number Publication Date
JP2024540402A true JP2024540402A (ja) 2024-10-31
JP2024540402A5 JP2024540402A5 (enExample) 2025-11-12

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527084A Pending JP2024540402A (ja) 2021-11-03 2022-11-02 新規オーリスタチン類似体およびその免疫複合体

Country Status (10)

Country Link
US (1) US20260131016A1 (enExample)
EP (1) EP4426714A4 (enExample)
JP (1) JP2024540402A (enExample)
KR (1) KR20240110584A (enExample)
AU (1) AU2022380491A1 (enExample)
CA (1) CA3236944A1 (enExample)
IL (1) IL312533A (enExample)
MX (1) MX2024005342A (enExample)
TW (1) TW202334176A (enExample)
WO (1) WO2023081230A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
KR20240110584A (ko) 2024-07-15
EP4426714A1 (en) 2024-09-11
TW202334176A (zh) 2023-09-01
AU2022380491A1 (en) 2024-05-30
MX2024005342A (es) 2024-09-27
WO2023081230A1 (en) 2023-05-11
CA3236944A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
US20260131016A1 (en) 2026-05-14
IL312533A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
CA2951368A1 (en) Auristatin derivatives and conjugates thereof
ES2867749T3 (es) Conectores y su aplicación con respecto a los CAF
TWI712605B (zh) 含有cti藥效基團之雙功能性細胞毒性劑
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
CN121574085A (zh) 缀合物及其用途
WO2024160176A1 (zh) 一类连接子药物及其抗体-药物偶联物的制备方法和应用
TW202400266A (zh) 配體藥物偶聯物及其應用
AU2022380491A1 (en) Novel auristatin analogs and immunoconjugates thereof
JP2025500404A (ja) 新規オーリスタチン類似体およびその免疫複合体
EP4471005A1 (en) Conjugate and use thereof
HK40115429A (en) Novel auristatin analogs and immunoconjugates thereof
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40117241A (en) Novel auristatin analogs and immunoconjugates thereof
WO2025176733A1 (en) Antibody-drug conjugates involving small molecule atr/chk1 inhibitors
JP2026500275A (ja) 細胞毒性化合物
WO2026065268A1 (en) Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
CN120513102A (zh) 一种抗体药物偶联物及其制备方法和用途
AU2024350816A1 (en) Auristatin derivative and antibody-drug conjugate thereof
HK1204273B (en) Cytotoxic peptides and antibody drug conjugates thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260807